Podcasts about life sciences practice

Channing Hamlet, Managing Director and Co-Founder of Objective, Investment Banking & Valuation, joins Amanda Ma, CEO & Founder of Innovate Marketing Group, to discuss the rising "flight to quality" in the event industry. Learn how consolidation is transforming the landscape — and how event businesses can adapt, scale, and thrive in a shifting market.About the guest:Channing Hamlet is the Managing Director and Co-Founder of Objective, Investment Banking & Valuation. He leads the firm's Business Services & Life Sciences Practice. With over 25 years of experience in investment banking and business valuation, Channing brings deep expertise and strategic insight to Objective's clients. His recent notable transactions include the sale of 360 Destination Management to H.I.G. Capital and Supreme to Trinity Hunt Partners. An active member of the Los Angeles advisor community, Channing has served on the boards of the Exit Planning Institute, ACG LA, and EO LA. He is also passionate about philanthropy, particularly through his involvement with Reality Changers.  Prior to joining Objective, Mr. Hamlet served as a Managing Director of Cabrillo Advisors, where he was instrumental in both leading their M&A execution and growing the valuation practice from inception into a national entity serving more than 700 clients in five years. Previously, he served as a Director at Vistage; Principal at LLR Partners, a $260 million private-equity firm; and member of Legg Mason's Investment Banking group. He has a Master's Degree in Operations Research and a Bachelor of Science in Mechanical Engineering from Cornell University. He holds FINRA Series 7, 63 and 79 licenses and is a Registered Representative of BA Securities LLC, Member FINRA SIPC.Connect with Channing Hamlet on LinkedIn hereRead about the sale of 360 Destination Management Group hereDownload the The Introspective CEO's Guide to Selling a Business, a high-level workbook covering key considerations for those contemplating a sale here.Objective, Investment Banking & Valuation is a leading firm serving middle market companies across key industries including Business Services, Consumer, Healthcare Tech, Life Sciences, Manufacturing, and Technology. We offer M&A advisory through our investment banking group and a full suite of valuation services for tax, financial reporting, and strategic planning. Since 2006, our team has completed over 500 M&A deals and thousands of valuations. Learn more at objectiveibv.comThis podcast episode is for informational purposes only and does not constitute investment, legal, or tax advice. Securities offered through BA Securities, LLC, Member FINRA, SIPC. Objective and BA Securities, LLC are separate, unaffiliated entities.EventUp is brought to you by Innovate Marketing Group. An award-winning Corporate Event and Experiential Marketing Agency based in Los Angeles, California. Creating Nationwide Immersive Event Experiences to help brands connect with people. To learn more, click here⁠⁠.Follow us!Find us on ⁠⁠LinkedIn, ⁠⁠⁠⁠EventUp Podcast LinkedIn⁠⁠ , and ⁠⁠Instagram

Sandy Vance and Jason Warrelmann, the VP of Healthcare & Life Sciences at UiPath, discuss how AI and agentic automation are transforming the healthcare space. Jason also offers customer use cases to expand on real-life digital transformations. UiPath and Jason were at the ViVe event in February; check out the recordings on the ViVE website.In this episode, they talk about:The role that automation plays in the healthcare space: Humans don't like being interoperability engines. Automation is a good universal API and it doesn't hallucinate. Studies show a high failure rate for AI projects across industries, including healthcare. A small pilot turns into a big expensive project involving different vendorsTechnology changes so quicklyWhat kind of ROI will CFOs see?Examples of how UiPath is helping healthcare organizations achieve their goals with AI and automation.A Little About Jason:Jason Warrelmann leads the Healthcare and Life Sciences Practice at UiPath, which focuses on transforming the healthcare landscape and developing capabilities, integrations, and reusable components that make UiPath a healthcare automation platform, not just a tool that works in healthcare.

The Asia Pacific region is fast becoming a global leader in medical technology, with artificial intelligence playing a crucial role in its transformation. From diagnostics to treatment and operational efficiency, AI is reshaping the industry in groundbreaking ways. Vikram Kapur, Head, Bain & Company’s Global Healthcare and Life Sciences Practice, shares insights on the key drivers of growth, the talent gap in AI and healthcare, and the future of medtech in the region as well as Bain & Co’s latest report on AI’s impact on medtech. See omnystudio.com/listener for privacy information.

In this episode of Business Ninjas, Josh Ensign, Managing Director for the Life Sciences Practice at Point B, joins Kelsey and talks about how Point B assists their clients with compliance and regulatory challenges, as well as the different industries they work with. About Point B:Trusted by the world's leading organizations, Point B is a consulting company that drives impact at the intersection of expertise, industry insight, and transformative technology. This collaborative approach enables you to solve your most important challenges by bringing together the right mix of talent and technology to deliver greater value and impact. With over 850 associates in the US and 3,000+ consultants around the world through their partnership with Nextcontinent, Point B works where you do to deliver the change you seek.Learn more: https://www.pointb.com/-----Do you want to be interviewed for your business?  Schedule time with us, and we'll create a podcast like this for your business:  https://www.WriteForMe.io/-----https://www.facebook.com/writeforme.iohttps://www.instagram.com/writeforme.io/https://twitter.com/writeformeiohttps://www.linkedin.com/company/writeforme/ https://www.pinterest.com/andysteuer/Want to be interviewed on our Business Ninjas podcast? Schedule time with us now, and we'll make it happen right away! Check out WriteForMe, more than just a Content Agency! See the Faces Behind The Voices on our YouTube Channel!

China's economy and business landscape have been going through significant changes. We speak with three experts who will help us understand those shifts and how multinationals can adapt their strategies to succeed in China. Our guests are Franck Le Deu, a leader of our Life Sciences Practice in China, Joe Ngai, chairman of our offices in Greater China, and Junna Shi, a partner who advises Chinese government institutions on industrial development, regional economic planning, and integrated regional development topics.    Related Insights The McKinsey Global Institute report we refer to in this episode: https://www.mckinsey.com/mgi/our-research/the-china-imperative-for-multinational-companiesMGI on LinkedIn Join our LinkedIn community of more than 91,000 members and follow us on X at @McKStrategy.  Explore our collection of Inside the Strategy Room episode transcripts on McKinsey.com. Join 90,000 other members of our LinkedIn community: https://www.linkedin.com/showcase/mckinsey-strategy-&-corporate-finance/See www.mckinsey.com/privacy-policy for privacy information

China's economy and business landscape have been going through significant changes. We speak with three experts who will help us understand those shifts and how multinationals can adapt their strategies to succeed in China. Our guests are Franck Le Deu, a leader of our Life Sciences Practice in China, Joe Ngai, chairman of our offices in Greater China, and Junna Shi, a partner who advises Chinese government institutions on industrial development, regional economic planning, and integrated regional development topics.    Related Insights The McKinsey Global Institute report we refer to in this episode: https://www.mckinsey.com/mgi/our-research/the-china-imperative-for-multinational-companiesMGI on LinkedIn Join our LinkedIn community of more than 91,000 members and follow us on X at @McKStrategy.  Explore our collection of Inside the Strategy Room episode transcripts on McKinsey.com. Join 90,000 other members of our LinkedIn community: https://www.linkedin.com/showcase/mckinsey-strategy-&-corporate-finance/See www.mckinsey.com/privacy-policy for privacy information

"Selling without selling" refers to an approach or technique that focuses on building authentic relationships with potential customers and meeting their needs without resorting to pushy sales tactics. The goal is to create a positive and genuine interaction with prospects, building long-lasting relationships.   This can be easier said than done, that is why our special guest, Mike Silverstein of Direct Recruiters, Inc shares how he applies this to his practice and he has helped developed multi-million dollar billers.    Mike is the Managing Partner of DRI's healthcare IT and life sciences practice. In 2014, Mike was inducted into the Pinnacle Society, which is the nation's premier consortium of top recruiters within the direct placement and search industry. In 2016, Mike was named one of the most influential millennials by Staffing Industry Analysts.   Episode Outline and Highlights   [04:28] How getting fired from his first job led … Mike got into recruitment. [08:16] Building a practice from scratch in the middle of a recession [17:15] Figuratively depositing in the emotional bank account - hear young Mike's strategy for building relationships with senior executives in transition. [22:30] Mike reveals why you should “Never sell on the first call!” [31:20] Practices on leads tracking and follow-up. [33:19] Why you must hire team members to complement what you're good at. [38:24] Lessons learned in trying to grow a team. [39:56] The one thing you cannot teach your team members. [43:41] Hiring, mentoring, and developing million dollar billers.   “Never Sell on the First Call!”   Mike revealed the best advice he got when he was just starting as a recruiter.    He shared, “I learned that if you can resist the urge to sell on the first call … you're going to land in the friend or, you know, consultant bucket versus the person that five minutes into a call is asking for something. And if you can resist the urge to sell on the first call, you'll have carte blanche to ask for stuff for the rest of your relationship because you've established yourself in the right part of somebody's brain.”   I believe that this approach has contributed greatly to Mike's success. Understanding the value of being genuine and authentic allowed him to gain respect from potential clients and other stakeholders. Mike shared how he applied these principles to grow a multi-million dollar practice.   Hiring, Mentoring, and Developing Million Dollar Billers   A fulfilling accomplishment in Mike's career is how he hired and developed million dollar billers in their firm. Some of the talent he hired as rookies have gone on to become Partners. What are the key factors in build a team of high performers?   Here are some insights that Mike shared:   You cannot teach self-motivation: “I think one of the things I learned is you can't teach motivation. Like people have to be self-motivated. You can teach the skill, but you can't teach them motivation.”  Build Relationships: Mike loves talking to people, whether it be candidates or senior executives, and would happily add value even if he is not pitching any business during the initial interactions. He described it as “depositing into the relationship bank”, which keeps him top-of-mind when there are positions that need to be filled. Be Top-of-Funnel Driven: “I've had to learn the hard way that you can't be relying on any one customer or any one relationship. And so I am obsessed with top of the funnel,” Mike says. Being consistent in top-of-funnel activities like marketing and business development is key to consistent billing.   Complement Your Strengths with the Right Team Members   Another topic that resonated with me is our discussion on the value of hiring the right team members. A lot of solo recruiters and recruitment entrepreneurs tend to attemp to do everything on their own. But the most successful business owners I know are those who know how to delegate and hire team members that complement their strengths.    Mike shared how this has been a game-changer for him when he hired an experienced partner to complement his strengths and weaknesses. He said, “And if recruiting is a combination of art and science, I'm the artist and she's the scientist.”   If you are a solo practitioner, you might be missing out on opportunities by not building a team. If you're in a boat rowing by yourself,you can only go so fast and so far. But if you have a whole crew who are rowing in the same direction, man, you can really motor!   Our Sponsor   This podcast is proudly sponsored by i-intro    i-intro® is an end-to-end retained recruitment platform. Their technology and methodology allow recruiters to differentiate themselves from the competition, win more retained business, bigger fees, and increase their billings. Their software combined with world-class training enables you to transition from transactional, contingency recruiter to consultative, retained recruiter. Instead of being perceived as a “me too” vendor, you'll be positioned as a “me only” solutions provider. Be sure to mention Mark Whitby or The Resilient Recruiter. Book your free, no-obligation consultation here: https://recruitmentcoach.com/retained   Mike Silverstein Bio and Contact Info   Mike Silverstein is the Managing Partner of DRI's Healthcare IT Division and Life Sciences Practice. In 2014, Mike was inducted into The Pinnacle Society, the nation's premier consortium of top recruiters within the direct placement and search industry. In 2016, Mike was named one of the most "" by Staffing Industry Analysts, the global advisor of staffing and workforce solutions.   Mike founded the Healthcare IT practice in 2008. Under his leadership, the Life Sciences Practice has expanded and the HIT practice area has grown significantly year-over-year. Additionally, in 2011, Mike helped found what is now DRI's Hospital IT group as a Managing Partner, which is concentrated largely on Hospital IT staffing and consulting. With a focus on recruiting from the Executive Level and C-Suite through individual contributor roles within healthcare software and services organizations nationwide, Mike's diverse background helps him to identify exceptional individuals from startup companies to Fortune 500 corporations. Mike's consultative style along with his personable approach enables him to develop trusted relationships with clients and investors in order to deliver high-caliber talent capable of leading companies in competitive and fast-changing business environments. Mike Silverstein is known as one of the top healthcare IT recruiters and life sciences recruiters in the United States.   Mike graduated Cum Laude in Marketing and Entrepreneurship from Miami University, Oxford, Ohio. He is a Cleveland sports fan, and enjoys music, socializing with friends, and discussing politics.   Mike on LinkedIn Direct Recruiters website link Direct Recruiters on Facebook Direct Recruiters on YouTube Direct Recruiters on Twitter   People and Resources Mentioned   Pinnacle Society The book mentioned: The Five Dysfunctions of a Team  Kasey Kaiser on LinkedIn  Dan Charney on LinkedIn Fernando Espinosa on LinkedIn  Norman Volsky on LinkedIn  Chris Shoettelkotte on LinkedIn  Rich Rosen on LinkedIn  Crelate - recruiting software   Connect with Mark Whitby Get your FREE 30-minute strategy call Mark on LinkedIn Mark on Twitter: @MarkWhitby Mark on Facebook Mark on Instagram: @RecruitmentCoach Related Podcast You Might Enjoy TRR#182 Growth Mindset: How to Conquer Self Doubt and Become a Top Biller, with Fernando Espinosa How to Build a $6M+ Practice by Hiring and Training Top Performers, with Norman Volsky How to Create a Unique Value Proposition and Sell Retained Executive Search, with Chris Shoettelkotte Think Like a Big Biller: How to Get Repeat Business and Referrals, with Rich Rosen Subscribe to The Resilient Recruiter     If you've been enjoying the podcast, please take two minutes to leave a review. Your review is greatly appreciated because it helps us attract a bigger audience and help more recruiters.  “Support the podcast and leave a review here”.    

We're back with Bates White for a deeper look into the world of economic consulting through a conversation with Amelia Irvine, a Manager in the firm's Life Sciences Practice.The wide-ranging discussions covers:How Amelia successfully transitioned from politics to consultingWhat a "normal" day-in-the-life of an economic consultant looks likeCritical cover letter do's and don'tsKey candidate qualities Bates White looks forThe Bates White case interview process - demystifiedWhy being able to get excited about dishwashers *may* mean you're cut out to be a consultantInterested in working for a firm like Bates White? Good news - the firm is hiring! See current openings here.Relevant LinksExplore careers at Bates WhiteFollow Bates White on LinkedInContact Bates White: careers@bateswhite.comGet a resume and cover letter editMBB application deadlines (Bain: June 25)Connect With Us Follow Management Consulted on LinkedIn, Instagram, and TikTok for the latest updates and industry insights. Email the Strategy Simplified team at podcast@managementconsulted.com with any questions or feedback. Partner with us by sponsoring an episode or advertising on Strategy Simplified. Check out our Media Kit for more information.

In this second episode of our Voices of CEO Excellence interview with Ken Frazier, the former executive chairman and CEO of Merck candidly reflects on how he managed past crises. Frazier discusses his decision-making process around the litigation trial concerning Merck's pain-relief drug Vioxx, and how his employees ensured that a potentially crippling cyber attack did not stop production of critical medicines. He also speaks about how his most important advisor, his wife Andrea, has kept him grounded.  Frazier spoke with Vik Malhotra, former chairman of McKinsey's Americas region and co-author of last year's New York Times bestseller, CEO Excellence: The Six Mindsets That Distinguish the Best Leaders from the Rest and Steve Van Kuiken, a former leader in our Life Sciences Practice and global leader of McKinsey Technology.  Listen to other episodes in our Voices of CEO Excellence series: Blackstone's chairman, CEO, and cofounder, Stephen Schwarzman Morgan Stanley's chairman and CEO, James Gorman Join our LinkedIn community of more than 89,000 members and follow us on Twitter at @McKStrategy. Explore our collection of Inside the Strategy Room episode transcripts on McKinsey.com Take a masterclass with 67 of the world's highest-performing CEOs and order your copy of the New York Times bestseller, CEO Excellence: The Six Mindsets That Distinguish the Best Leaders from the Rest.  See www.mckinsey.com/privacy-policy for privacy information

In this second episode of our Voices of CEO Excellence interview with Ken Frazier, the former executive chairman and CEO of Merck candidly reflects on how he managed past crises. Frazier discusses his decision-making process around the litigation trial concerning Merck's pain-relief drug Vioxx, and how his employees ensured that a potentially crippling cyber attack did not stop production of critical medicines. He also speaks about how his most important advisor, his wife Andrea, has kept him grounded.  Frazier spoke with Vik Malhotra, former chairman of McKinsey's Americas region and co-author of last year's New York Times bestseller, CEO Excellence: The Six Mindsets That Distinguish the Best Leaders from the Rest and Steve Van Kuiken, a former leader in our Life Sciences Practice and global leader of McKinsey Technology.  Listen to other episodes in our Voices of CEO Excellence series: Blackstone's chairman, CEO, and cofounder, Stephen Schwarzman Morgan Stanley's chairman and CEO, James Gorman Join our LinkedIn community of more than 89,000 members and follow us on Twitter at @McKStrategy. Explore our collection of Inside the Strategy Room episode transcripts on McKinsey.com Take a masterclass with 67 of the world's highest-performing CEOs and order your copy of the New York Times bestseller, CEO Excellence: The Six Mindsets That Distinguish the Best Leaders from the Rest.  Join 90,000 other members of our LinkedIn community: https://www.linkedin.com/showcase/mckinsey-strategy-&-corporate-finance/See www.mckinsey.com/privacy-policy for privacy information

As CEO of Merck, Ken Frazier gained the respect of his employees, shareholders, and the broader community - both through the company's performance during his 11-year tenure and also through his handling of several tests of his leadership. Now Merck's former executive chairman, he recently shared how his experience growing up during the Civil Rights Movement shaped his career, how he ensured that science stayed at the core of Merck's mission, and how he sees business's role in society. In this, the first of two new episodes Frazier recorded for our Voices of CEO Excellence series, he spoke with Vik Malhotra, former chairman of our Americas region and co-author of last year's New York Times bestseller, CEO Excellence: The Six Mindsets That Distinguish the Best Leaders from the Rest and Steve Van Kuiken, a former leader in our Life Sciences Practice and global leader of McKinsey Technology.  Listen to other episodes in our Voices of CEO Excellence series: Blackstone's chairman, CEO, and cofounder, Stephen Schwarzman Morgan Stanley's chairman and CEO, James Gorman Join our LinkedIn community of nearly 90,000 members and follow us on Twitter at @McKStrategy. Explore our collection of Inside the Strategy Room episode transcripts on McKinsey.com Take a masterclass with 67 of the world's highest-performing CEOs and order your copy of the New York Times bestseller, CEO Excellence: The Six Mindsets That Distinguish the Best Leaders from the Rest.    See www.mckinsey.com/privacy-policy for privacy information

As CEO of Merck, Ken Frazier gained the respect of his employees, shareholders, and the broader community - both through the company's performance during his 11-year tenure and also through his handling of several tests of his leadership. Now Merck's former executive chairman, he recently shared how his experience growing up during the Civil Rights Movement shaped his career, how he ensured that science stayed at the core of Merck's mission, and how he sees business's role in society. In this, the first of two new episodes Frazier recorded for our Voices of CEO Excellence series, he spoke with Vik Malhotra, former chairman of our Americas region and co-author of last year's New York Times bestseller, CEO Excellence: The Six Mindsets That Distinguish the Best Leaders from the Rest and Steve Van Kuiken, a former leader in our Life Sciences Practice and global leader of McKinsey Technology.  Listen to other episodes in our Voices of CEO Excellence series: Blackstone's chairman, CEO, and cofounder, Stephen Schwarzman Morgan Stanley's chairman and CEO, James Gorman Join our LinkedIn community of nearly 90,000 members and follow us on Twitter at @McKStrategy. Explore our collection of Inside the Strategy Room episode transcripts on McKinsey.com Take a masterclass with 67 of the world's highest-performing CEOs and order your copy of the New York Times bestseller, CEO Excellence: The Six Mindsets That Distinguish the Best Leaders from the Rest.    Join 90,000 other members of our LinkedIn community: https://www.linkedin.com/showcase/mckinsey-strategy-&-corporate-finance/See www.mckinsey.com/privacy-policy for privacy information

Bates White is a leading economic consulting firm with tons of interesting opportunities for a range of talented folks. Today, we're excited to bring on Scott Weishaar - a Partner in the firm's Life Sciences Practice - to share what makes the firm unique in the consulting landscape.The conversation covers the below (and a whole lot more):What the heck is economic consulting?Clients the firm servesCulture at the firmWhat differentiates Bates White in the marketPromotions at the firmBates White's (hybrid) working modelCover letter and general recruiting tips for candidatesThe firm is actively hiring for a number of roles - learn more and apply.Relevant LinksExplore careers at Bates WhiteFollow Bates White on LinkedInSee our in-depth write-up on Bates WhitePartner LinksExplore Stax careersLearn more about IGS careersConnect With Us Follow Management Consulted on LinkedIn, Instagram, and TikTok for the latest updates and industry insights. Email the Strategy Simplified team at podcast@managementconsulted.com with any questions or feedback. Partner with us by sponsoring an episode or advertising on Strategy Simplified. Check out our Media Kit for more information.

The healthcare sector has been in sharp focus over the last few years, from the ability of health infrastructure to cope with the pandemic, to the role of the private operators working alongside the public system.Sean Aylmer speaks to Lucy d'Arville, head of Bain's Australia and New Zealand Healthcare and Life Sciences Practice, about the resilience of the sector and what the future holds.Find out more: https://fearandgreed.com.auSee omnystudio.com/listener for privacy information.

Just a few words can make a big difference, and the right words can hit you at the right time to become transformative. My next guest Clifford Barnes embraces every challenge as an opportunity to empower change through dynamic discussion.  He brings the issues of healthcare law to his table.  Barnes believes that no matter what position or condition you are in, improving health equity in this country will give you an equal shot. How we combine health equity and value-based purchasing in the Medicaid space will address the health inequities in which health disparities exist. Barnes has reinvented himself around health equality and values based contracting as a real incentive for providers, payors, and government to resolve these issues through appropriately structuring the healthcare landscape.   One person can make a difference! Prioritizing health equity in the boardroom is his goal. Clifford Barnes is a Shareholder of Epstein Becker Green in the Health Care and Life Sciences Practice in the firm's Washington, DC and New York offices and has been employed with EBG for over 40 years.  Clifford Barnes is a transactional attorney and represents providers, including home health and nursing facilities, hospitals, hospital systems, and ancillary service companies and managed care organizations specializing in representing Medicaid managed care companies; non-profit associations, including Medicaid Health Plans of America.  Mr. Barnes is the co-founder of Medical Health Plans of America, the national trade association for Medicaid managed care plans.  Mr. Barnes represents health plans in provider contracting, including value based contracting. Mr. Barnes counsels clients on mergers, acquisitions, joint ventures, contracting, regulatory and insurance issues, and compliance program effectiveness. Most recently, Mr. Barnes has worked with home health companies in connection with a temporary suspension from Medicaid.  Mr. Barnes has also worked with EBG Advisors, a consulting firm affiliated with Epstein Becker Green, to implement National Health Insurance in the British Virgin Islands.  Mr. Barnes has been recognized as a Super Lawyer in Health Care Law. Prior to law school, Mr. Barnes worked several years in health administration.  Mr. Barnes has a Bachelor's in Business Administration from Pace University, an MBA in Health Administration from Cornell University and a Juris Doctorate from the University of Virginia, where he served on the Editorial Board of the Journal of Natural Resources Law.

In this fourth episode of Up Close, Mark Reed-Edwards talks with our healthcare and life sciences practice leader at HFS, Rohan Kulkarni. Rohan looks back on the past few months and shares what he has published right up to the most recent research on HFSResearch.com. Highlights of some recent work in Healthcare & Life sciences include: The release of the bi-annual HCP Top 10 with 18 service providers Our views on Metaverse and healthcare will lay to rest the hype vs. reality A recent study indicated how social determinants of Health solutions are commercially viable A digital round table about personalizing healthcare with cloud-enabled data and analytics The research on how service provider capabilities have matured in the LS industry to drive disruption and redefine GT Looking ahead to the next couple of months, Rohan has some interesting work waiting in the wings, including: We just launched the 2022 Healthcare Services Top 10 and expect to evaluate close to 30 service providers across multiple market segments Our research on Amazon's acquisition of OneMedical will disrupt health insurance for primary care in the US – our prediction is coming true Our research on the impact of the recession on healthcare Our research on why not having a chief medical officer in the ranks of service providers leadership is missing a trick We'll be back next month with another update. Until then, keep an eye on HFSResearch.com for Rohan's latest work, and drop him a line if you have any questions.

In this third episode of Up Close, Mark Reed-Edwards talks with our healthcare and life sciences practice leader at HFS, Rohan Kulkarni. Rohan looks back on the past few months and shares what he has published right up to the most recent research on HFSResearch.com. Highlights of some recent work in Healthcare & Life sciences include: Lanch of our very first Digital Health Primary Care market scan Interview on the blog with Phil on the new market opportunities with self-insured employers Videocast with Dr. Ravula of EXL Health that discusses Moral Determinants of Health (MDoH) A POV with Dr. Prabhu of HCL to discuss the impacts of Price Transparency across the healthcare ecosystem Perspective on Roe v Wade Looking ahead to the next couple of months, Rohan has some interesting work waiting in the wings, including: The bi-annual HCP Top 10 with 18 service providers How our views on Metaverse and healthcare will lay to rest the hype vs. reality The research on Social Determinants of Health (SDoH) We'll be back next month with another update. Until then, keep an eye on HFSResearch.com for Rohan's latest work, and drop him a line if you have any questions.

Ever wondered what it's like to work for NES Fircroft? In this series, our colleagues from across the globe share their experiences working for the world's largest engineering staffing company! This time we spoke with, Benjamin Hippolyte - Head of Life Sciences Practice - France. We asked Ben: - What work are you most proud of? And why? - How would you describe the office culture at NES Fircroft? - What are the things that keep you at NES Fircroft? - What are 3 words to describe working at NES Fircroft Listen now! Do you want to be part of something big? We're enabling the progression of global healthcare. In just 10 years we've more than doubled our international office count, tripled our internal headcount, made eight acquisitions and secured a spot on Staffing Industry Analysts' largest engineering recruitment firms. We know what we're doing. We're currently growing our European Life Science division to further establish our brand as one of the top tier suppliers for the Pharma/Biotech and Devices industries. Do you want to be part of this growth? Share your LinkedIn profile with us. https://www.linkedin.com/organization/202782/campaign/9e0a045c-b1d2-4e07-b104-ca962ac8fe7f

In this episode of Up Close, Mark Reed-Edwards talks with our healthcare and life sciences practice leader at HFS, Rohan Kulkarni. Rohan looks back on the past few months and shares what he has published right up to the most recent research on HFSResearch.com. Highlights of recent publications include: New Life Sciences-specific page at HFSResearch.com The PoV on RPMs The PoV on Moral Determinants of Health Other couples of data viewpoints around Healthcare and Lifesciences Looking ahead to the next couple of months, Rohan has some interesting work waiting in the wings, including: Healthcare Provider services Top 10 in June timeframe from a very healthy slate of some 20 service providers Exploring the understated but hugely impactful shift of health plans from insurance to healthcare services How our views on Metaverse and healthcare will lay to rest the hype vs. reality We'll be back next month with another update. Until then, keep an eye on HFSResearch.com for Rohan's latest work, and drop him a line if you have any questions.

On this episode host Sandy Vance talks t Jason Warrelmann, Global Director of Healthcare and Life Sciences at UiPath about user interface automation. Jason leads the Healthcare and Life Sciences Practice at UiPath, which focuses on transforming the Healthcare landscape and developing capabilities, integrations, and reusable components that make UiPath a healthcare automation platform and not just a tool that works in healthcare. UiPath is the only end-to-end, enterprise-ready automation platform that can grow with customers on their digital transformation journey. From supply chain to HR and compliance to patient care – Jason shares how partnering with UiPath can remove a lot of the administrative burden to free up the healthcare workforce to do what they do best.

In this first episode of Up Close, Mark Reed-Edwards talks with our healthcare and life sciences practice leader at HFS, Rohan Kulkarni. Rohan looks back on the past few months and shares what he has published right up to the most recent research on HFSResearch.com. Highlights of recent publications include: The Life Sciences services Top 10 report The Healthcare & Life Sciences research agenda A piece on how digital health is disrupting the primary care space More recently, Rohan published insights on how self-insured employer enrolment has overtaken fully insured. In addition, he launched the Healthcare Provider services Top 10 report, which will be published in the coming months. Looking ahead to the next couple of months, Rohan has some interesting work waiting in the wings, including: Digital Health's Most Promising; profiles of those that hold the most promise to impact the triple aim of care A first of its kind by industry analyst; a perspective of Moral Determinants of Health Perspectives on wearables and its impacts, Metaverse in Healthcare and Price transparency We'll be back next month with another update. Until then, keep an eye on HFSResearch.com for Rohan's latest work and drop him a line if you have any questions.

Marion Spears Karr and Bonnie discuss the contemporary skill sets required of executive leaders and why there is a mismatch with how organizations recruit leaders today. Important Links: https://www.linkedin.com/in/marionspearskarr/ www.comharpartners.com Learn more about your ad choices. Visit megaphone.fm/adchoices

Although there are 155 million registered donors or nearly half of US adults, transplant waitlists remain long. While the US leads the world in deceased organ donation rates with steady growth and clinical innovations that have helped address the need, there is major room for improvement. Says Alex Glazier, CEO of New England Donor Services, with the right systemwide interventions, deceased donor kidney transplantation could jump by 61% by 2026. Dan Shellenbarger, Partner in Oliver Wyman's Health and Life Sciences Practice, sat down with Alex Glazier, CEO of New England Donor Services, and Kevin O'Connor, CEO of LifeCenter Northwest on the Oliver Wyman Health Podcast to talk about ways in which their organizations are driving improvements in organ recovery and transplantation and why older donors are a key demographic of focus.

In healthcare, is IoMT the Internet of Medical Things or the “Internet of Many Threats”? We are now in a whole new norm with global connected healthcare bracing for increasing cyber data breaches.  Listen to the premiere episode of Season 2 featuring Florence Hudson, Executive Director of Northeast Big Data Innovation Hub, as she explains the need for addressing cybersecurity, together with the IEEE SA Healthcare and Life Sciences Practice, a global program encompassing open collaborative innovation, systems thinking, and trust security solutions to create, capture, and secure value in the global connected healthcare system.   Related Resources: IEEE SA Healthcare and Life Sciences Practice IEEE SA Global Connected Healthcare Cybersecurity Virtual Workshop Series IEEE P2933, Standard for Clinical Internet of Things (IoT) Data and Device Interoperability with TIPPSS - Trust, Identity, Privacy, Protection, Safety, Security

Addressing racism is a marathon, not a sprint. Healthcare leaders must be willing to take the first step to initiate heavy conversations that drive progress. Says Dr. Nzinga Harrison, Co-Founder and Chief Medical Officer of Eleanor Health, there is a direct correlation between someone experiencing weathering (a "fight or flight" physiological reaction) to them possibly developing health problems like high blood pressure, obesity, cardiovascular illness, depression, anxiety, substance use disorders, and more down the road. To learn more about weathering, health equity, and more, Elizabeth Southerlan, Principal in Oliver Wyman's Health and Life Sciences Practice, sat down with Dr. Harrison to talk about the psychological burden of racism as an independent risk factor for health. For more information, follow us on Twitter @OWHealthEditor, read our online healthcare publication, Oliver Wyman Health, at health.oliverwyman.com, and see our guest roster: oliverwyman.com/oliverwymanhealthpodcast. Questions or comments? Email Oliver Wyman Health's Editor, jacqueline.dichiara@oliverwyman.com.

In this episode, Mike and I discuss his new blog post about the 10 risks life science companies will face in 2021. Mike Cremeans Bio: He leads the Life Sciences Practice for Hylant, whose mission is to strengthen the businesses, employees and communities of our client family by embracing them as our own. He is a client facing risk strategist and recognized subject matter expert for Life Sciences related products and services and partner with his customers to identify, simplify and translate complicated risks/situations into understandable concepts and practical solutions.

In this episode, Kevin, Neil and I discuss how to think about intellectual property as a medical device company, when to think about it, and how IP fits into the overall company strategy. Neil Thompson Bio: Neil is a patent agent who worked for years in the medical device industry as a product development engineer. He became a patent agent while working as an engineer to lessen the load of outside counsel drafting patent applications. Working at both startups and larger companies, Neil has been involved with the patenting process in both environments. In addition to drafting and prosecuting patent applications, Neil has led workshops in IP for SCORE and IP webinars for Orthopedic Research Society and the Society for Biomaterials. He currently hosts a meetup group for patent practitioners. Right before joining Torrey Pines Law Group, he worked as a freelance patent agent. He also uses his medical device background to advise small companies on packaging design and development. Neil is also passionate about public speaking for those in STEM. He created a course, Teach the Geek to Speak, to help engineers and scientists with their public speaking, especially when presenting in front of decision makers and those outside of STEM. He is also the author of a children's book, “Ask Uncle Neil: why is my hair curly?” The story focuses on Neil's nephew asking him why his hair is the way it is, and Neil uses science to answer the question. Neil received a Bachelor of Science degree in Materials Engineering from the University of Toronto, and graduate degrees in Bioengineering and Biomedical Engineering from Clemson University and Columbia University, respectively. He is also a Professional Engineer. Kevin Buckley Bio: I am first, and foremost, a patent attorney. There are currently about 30,000 of us worldwide, and I am proud to be a part of this group. As a *biotech* patent attorney, however, I focus on helping our clients protect and bring lifesaving technologies to the world. This certainly involves international patent law, but also involves international commercial competition, government regulations, litigation, medical device/drug/biological regulatory approvals, product branding, R&D strategy, and business strategy. I am a biochemist by training but spent the past 20+ years as a patent attorney helping our clients commercialize their innovations. I was previously: · a partner in a large US law firm where I led the Life Sciences Practice, · Chief Legal Officer to the Research Foundation of the largest US university, and · in-house counsel to a variety of startup companies where I developed complex legal strategies for commercializing artificial intelligence (AI) implemented technologies. Technical fields in which I specialize include medical device, biotechnology, pharmaceutical, diagnostics, and AI technologies.

Artificial intelligence (AI) is a burgeoning sector for investors and companies alike, but the unclear regulatory landscape for the use of AI in healthcare may cause headwinds that prevent it from achieving its full potential. The US Food and Drug Administration (FDA) asserts broad authority over medical devices, from toothbrushes to high-tech implants, under a decades-old regulatory framework. Recent advances in medical technology, including use of AI and machine learning, which are becoming increasingly integrated into traditional products and have accelerated the creation of novel devices that have the potential to revolutionize healthcare, but are nonetheless subject to a dated regulatory regime that in some ways is ill-suited to this cutting-edge technology. How must the FDA evolve its regulatory framework to realize the untapped potential of AI and machine learning, and what actions has it taken to date to support these technological advances? In this episode of Connected With Latham, Bay Area partner Luke Bergstrom, Global Vice Chair of the Mergers & Acquisitions Practice and the Technology Industry Group, discusses the future of FDA regulation of AI machine learning and the key considerations for investors and companies with Washington, D.C. partners Ben Haas and Elizabeth Richards, members of the Healthcare and Life Sciences Practice.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York’s Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York’s Disciplinary Rules to Latham & Watkins LLP, 885 Third Avenue, New York, NY 10022-4834, Phone: 1.212.906.1200

Drug discovery is just one of the fields where AI has become indispensable in healthcare. Decentralized trials and personalized treatments hold promise of enormous breakthroughs as well. We asked Mark Lambrecht, Director of Global Health & Life Sciences Practice at SAS to take a snapshot of the state of play of AI in clinical research and to tell us what to expect down the road. All AI Studio/MI Stúdió episodes and the latest on AI in Hungary and the CEE region are available at www.ai-hungary.com. All rights reserved. This show is the property of Digitális Jólét Nonprofit Kft. Music by: audionautix.com

In this episode I speak with Dave Dykeman, a Co-Managing Partner of the Boston office of Greenberg Traurig.  Dave and I met almost 20 years ago, not long after he moved to Boston and since that time I’ve watched his career take off as he has successfully built an IP practice in the life sciences.  Whenever I coach lawyers on marketing and business development, my starting point is getting my clients to define their ideal client.  While this doesn’t always include what industries they serve, having an industry focus is a good way to differentiate yourself. In a crowded marketplace for legal services, it is critical to define your niche and find ways to make yourself memorable.  While work ultimately comes from the relationships you build with clients, potential clients and referral sources, “choosing your lane” is the best starting point. My guest, Dave Dykeman, is someone who has not only clearly defined himself as a lawyer, but over the last two decades, he has done an outstanding job of building relationships that have been critical to his success.   In this episode, we’ll be discussing how Dave built that reputation, grew his practice, and what it has been like to move into a management role at an AmLaw100 firm.  He talks about coming to Boston, a city where he didn't know anyone. David Dykeman, serves as Co-Managing Shareholder of Greenberg Traurig's Boston office and co-chairs the firm's global Life Sciences & Medical Technology Group.  He is a registered patent attorney with more than 23 years of experience in patent and intellectual property law. David's practice focuses on securing worldwide intellectual property protection and related business strategy for high tech clients, with particular experience in life sciences, medical devices, robotics, materials, and information technology. David provides strategic patent portfolio development and intellectual property advice for clients including major research institutions, multinational corporations, and start-up companies. He also performs patent due diligence to assess patent portfolios for venture capital investment, mergers and acquisitions, and licensing opportunities. He is a prolific writer and speaker on intellectual property law.  He is also someone who has held numerous leadership roles in bar associations, industry groups, and philanthropic organizations. David is the founding co-chair of the ABA’s Medical Devices Committee. He was honored as one of Boston's "40 Under 40" innovative business leaders by the Boston Business Journal and was named to the "40 Medtech Innovators Under 40" list by Medical Device & Diagnostic Industry (MD+DI) Magazine. David has also been named one of the top 250 Patent and Technology Licensing Practitioners in the world by Intellectual Asset Management (IAM) Magazine, an "IP Star" by Managing IP magazine, a "Life Science Star" by LMG Life Sciences, one of the World's Leading IP Strategists in the IAM 300, and listed in Chambers as an IP practitioner. Additional Resources Episode 39-An In-house Career in the Life Sciences 47 Inexpensive ways to Build Business Relationships Episode 18-Starting Business Conversations at Networking Functions and Beyond Defining Your Target is the First Step in Effective Marketing

Virtual Healthcare in the Age of COVID: A Conversation with Owen Tripp ’01 CEO and Co-founder, Grand Rounds and Joanne Berger-Sweeney President and Trinity College Professor of Neuroscience Thursday, June 4, 2020 Join us to discuss emerging healthcare trends which are highlighting the need for change to the American healthcare system. Discussion will include the benefits of virtual care both during and after a pandemic and its place in an evolving healthcare landscape, with special emphasis on telemedicine and how it will evolve in the post-COVID-19 landscape. As co-founder and CEO of Grand Rounds, Owen believes that patients will achieve better healthcare outcomes through the intersection of technology, medical expertise, and extraordinary patient care. Prior to Grand Rounds, Owen co-founded Reputation.com and grew the company into the worldwide leader in online reputation and privacy management; he also held leadership positions at eBay and Accenture (Health and Life Sciences Practice). Owen received a BA with honors from Trinity College and received an MBA from Stanford Graduate School of Business. Owen’s been recognized among the World Economic Forum’s Global Technology Pioneers, Goldman Sachs’ Top 50 Builders + Innovators and Rock Health’s Most Beloved CEOs.

Navvis, a St. Louis-based population health company, and SSM Health, a nearly $8 billion health system in the Midwest, announced a holistic, data-driven, and consumer-focused partnership last year to design and operate a new value-based care delivery model. In this episode of the Oliver Wyman Health Podcast, Bryce Bach, Principal in Oliver Wyman's Health & Life Sciences Practice, sat down with Mike Farris, Navvis' Chairman and Chief Executive Officer, and Carter Dredge, SSM Health's Chief Transformation Officer, at the Oliver Wyman Health Innovation Summit in Chicago to learn more about their challenges and lessons so far. Check out part 1 here: https://health.oliverwyman.com/2019/11/podcast--navvis-and-ssm-health-s-partnership-.html More From This Episode: -- [Carter] "It's a misnomer for health systems to say, 'I'm just going to wait until 60 percent of my business is in risk until I change.' The reality is, if you're any system of any material size, no one is just going to give you that much risk right out of the gate. You've got to figure out how to identify problems for specific populations and fix them." -- [Mike] "You've got to do your diligence upfront. You've got to frame the risk. If you don't move, you've got to have a path ahead where you know where the pockets of value are that you're going to go after and can create a funding pool for re-investment. So innovation becomes self-sustaining." -- [Carter] "There is a latent opportunity in the front line when it comes to our experts. They know how to do a lot of our work way better than we do. We just need to give them a forum so they can see how [our vision] translates to patients. And if we can do that, look out. I literally see a day when we will be chasing to catch up with our front line." For more information, follow us on Twitter @OWHealthEditor, read our online healthcare publication at health.oliverwyman.com, and see our guest roster: oliverwyman.com/oliverwymanhealthpodcast. Questions or comments? Email Oliver Wyman Health's Editor, jacqueline.dichiara@oliverwyman.com.

Dan Kiely, Consultant in Odgers Interim's Independent Healthcare & Life Sciences Practice, discusses the challenges facing independent hospital and care home groups in light of dwindling government funding for UK healthcare services   Presenter, Grant Speed, Managing Director, Odgers Interim

In the final episode of our series, Evjatar (Evi) Cohen, Appian’s Vice President for the Life Sciences Practice discusses how Life Sciences organizations are navigating the move to the cloud. Industry topics include transforming the product lifecycle, clinical trials and contact research organizations (CROs), patient simplicity, and shifting industry attitudes towards moving to the cloud. Abby Jacobs serves as contributing host.

In the final episode of our series, Evjatar (Evi) Cohen, Appian’s Vice President for the Life Sciences Practice discusses how Life Sciences organizations are navigating the move to the cloud. Industry topics include transforming the product lifecycle, clinical trials and contact research organizations (CROs), patient simplicity, and shifting industry attitudes towards moving to the cloud. Abby Jacobs serves as contributing host.

In Part Two of this series, Evjatar (Evi) Cohen, Appian’s Vice President for the Life Sciences Practice discusses the different stages and systems that support the product life cycle and the digital transformation challenges organizations face. Industry topics include transforming the product lifecycle, clinical trials and contact research organizations (CROs), patient simplicity, and shifting industry attitudes towards moving to the cloud. Abby Jacobs serves as contributing host.

In Part Two of this series, Evjatar (Evi) Cohen, Appian’s Vice President for the Life Sciences Practice discusses the different stages and systems that support the product life cycle and the digital transformation challenges organizations face. Industry topics include transforming the product lifecycle, clinical trials and contact research organizations (CROs), patient simplicity, and shifting industry attitudes towards moving to the cloud. Abby Jacobs serves as contributing host.

In Part One of this series, Evjatar (Evi) Cohen, Appian’s Vice President for the Life Sciences Practice discusses innovation, digital transformation and his predictions on the forces shaping the life sciences industry. Topics include transforming the product lifecycle, clinical trials and contact research organizations (CROs), patient simplicity, and shifting industry attitudes towards moving to the cloud. Abby Jacobs serves as contributing host.

In Part One of this series, Evjatar (Evi) Cohen, Appian’s Vice President for the Life Sciences Practice discusses innovation, digital transformation and his predictions on the forces shaping the life sciences industry. Topics include transforming the product lifecycle, clinical trials and contact research organizations (CROs), patient simplicity, and shifting industry attitudes towards moving to the cloud. Abby Jacobs serves as contributing host.

David Katz, Senior Audit Manager in EisnerAmper’s Technology and Life Sciences Practice, discusses Amazon’s recent purchase of Middle Eastern e-commerce site Souq. Katz tells us about Souq, the Middle Eastern e-tail landscape, what the deal entailed, and why this is a key acquisition for Amazon.

David Katz, Senior Audit Manager in EisnerAmper’s Technology and Life Sciences Practice, discusses the commercial drone market, including potential markets, barriers to entry, and where capital investment is headed.

David Katz, Senior Audit Manager in EisnerAmper’s Technology and Life Sciences Practice, discusses some of the financial aspects of virtual reality, such as investment, valuation, revenue recognition and more.

In this episode of TechTalk, Dave Katz, Senior Audit Manager in EisnerAmper’s Technology and Life Sciences Practice, and Richard Colloca, Partner-in-Charge of EisnerAmper’s Food and Beverage Group, discuss Amazon’s plan to use “Just Walk Out Technology” to remove the lines, checkout counters and registers from your food shopping experience. The pair looks at the technology behind Amazon Go, potential speedbumps, and what it could mean for other bricks-and-mortar grocery chains.

In this episode of TechTalk, David Katz, Senior Audit Manager in EisnerAmper’s Technology and Life Sciences Practice, tells us about this space age technology that could revolutionize personal travel and commercial traffic sooner than you may think.

In this episode of TechTalk, David Katz, Senior Audit Manager in EisnerAmper’s Technology and Life Sciences Practice, gives a “state of the union” on self-driving cars, an overview of Uber’s unique experiment in Pittsburgh, and a glimpse of what we can expect in the marketplace over the next few years.

Todd is Head of North America, Oliver Wyman Health and Life Sciences Practice. We interviewed Todd at the Oliver Wyman Health Innovation Summit held in October, 2015.

Terry is Global Managing Partner, Oliver Wyman Health and Life Sciences Practice. We interviewed her at the Oliver Wyman Health Innovation Summit held in October, 2015.

John is Partner, Oliver Wyman Health and Life Sciences Practice. We interviewed him at the Oliver Wyman Health Innovation Summit held in October, 2015.

Bruce is the Chief Medical Officer for Oliver Wyman's Health and Life Sciences Practice. We interviewed him at the Oliver Wyman Health Innovation Summit held in October, 2015.

Tom is Partner and US Market Leader, Oliver Wyman Health and Life Sciences Practice. We interviewed Tom at the Oliver Wyman Health Innovation Summit held in October, 2015.

Welcome to the Pharmaguy episode 111 "Pharmacy Podcast Show" who created the ®. (aka, John Mack), and is the creator of Pharma Marketing Blogand the publisher of Pharma Marketing News. Follow @Pharmaguy™ on Twitter and Facebook.Pharma Marketing NetworkPharmaguy™ John Mack, President of VirSci Corporation, is an experienced executive with a background in pharmaceutical marketing communications, interactive technologies, and medical privacy. Mr. Mack is currently a principal consultant with VirSci Corporation, where he provides global pharmaceutical and health care industry clients with marketing communications, competitive market intelligence, and privacy/security consulting services. Previously, Mr. Mack was a consultant in the Life Sciences Practice at Answerthink, where he managed projects such as pharmaceutical DTC and physician web site development, privacy policy assessments, and HIPAA awareness workshops for healthcare providers. Mr. Mack also created and managed PharmInfoNet, a privately owned "Top 20 Health Site" focused on drug information content and databases for physicians and pharmacists. In 1999, he sold this web site to Mediconsult and became their Director of Drug Information. Mr, Mack is Publisher and Editor of  and moderates the PHARMA-MKTING on-line discussion Forum, both essential components of the Pharma Marketing Network.Pharma Marketing News See omnystudio.com/listener for privacy information.